Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sana Biotechnology ( (SANA) ) has provided an announcement.
On June 5, 2025, Sana Biotechnology held its annual meeting of stockholders where all nominees were elected as Class I directors for a three-year term. Additionally, stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (SANA) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Sana Biotechnology stock, see the SANA Stock Forecast page.
Spark’s Take on SANA Stock
According to Spark, TipRanks’ AI Analyst, SANA is a Underperform.
Sana Biotechnology’s overall stock score is primarily impacted by significant financial challenges, including consistent losses and a lack of revenue. Despite some improvements in balance sheet stability and operating cash flow, the bearish technical indicators and negative valuation metrics underscore the need for strategic changes to achieve growth and profitability.
To see Spark’s full report on SANA stock, click here.
More about Sana Biotechnology
Sana Biotechnology, Inc. operates in the biotechnology industry, focusing on developing and commercializing advanced therapies for various diseases.
Average Trading Volume: 3,712,261
Technical Sentiment Signal: Sell
Current Market Cap: $523.3M
For a thorough assessment of SANA stock, go to TipRanks’ Stock Analysis page.